AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12912723
Drug: Argatroban (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (2 micro g/kg per minute, adjusted to maintain aPTT at 1.5 to 3 times baseline for 5 to 7 days)
Trial: 26506138
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 2% topical solution BID
Trial: 7645037
Drug: BT563 (murine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (murine IgG1 anti-IL-2R antibody)
Trial: 25828172
Drug: Cognitive existential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive existential couple therapy (CECT)
Trial: 23328270
Drug: EZG 200
RxNorm normalized name: EZG
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZG 200 mg + ethanol 1 g/kg
Trial: 23328270
Drug: Ethanol 1
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 1 g/kg
Trial: 23328270
Drug: EZG 200
RxNorm normalized name: EZG
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZG 200 mg
Trial: 19447249
Drug: Sequential docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential docetaxel after anthracycline chemotherapy (FEC for four cycles followed by docetaxel 100 mg/m2 for four cycles)
Trial: 19447249
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (sequential docetaxel)
Trial: 14977675
Drug: Brace-only treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace-only treatment
Trial: 11345223
Drug: Ritonavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (600 mg twice daily)
Trial: 11345223
Drug: Indinavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (800 mg 3 times daily)
Trial: 11345223
Drug: Ritonavir/saquinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir/saquinavir (400 mg each twice daily)
Trial: 11345223
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in PI treatment
Trial: 1119588
Drug: Psychoanalytically oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytically oriented therapy
Trial: 9696508
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with imipramine
Trial: 1583824
Drug: Heparin (H)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin (H)
Trial: 2809693
Drug: Cefixime 200
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 200 mg b.i.d. for 10 to 11 days
Trial: 2809693
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg t.i.d. for 10 to 11 days
Trial: 30849250
Drug: Remifentanil patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil patient‐controlled intravenous labor analgesia (Group A)
Trial: 27966237
Drug: Rilotumumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (15 mg/kg), Epirubicin (50 mg/m2), Cisplatin (60 mg/m2), Capecitabine (625 mg/m2 twice daily)
Trial: 17828747
Drug: High-dose glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoids (prednisone or dexamethasone)
Trial: 17828747
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ACTH (LD-ACTH) stimulation
Trial: 16796788
Drug: Panitumumab as
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab as a single agent
Trial: 10078539
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg, 3 times a day for 4 days) + glyceryl trinitrate (0.5 mg/mL infusion)
Trial: 10078539
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg) + amlodipine
Trial: 7735024
Drug: Taper with
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper with placebo gum
Trial: 7735024
Drug: Taper with
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper with active gum
Trial: 1708984
Drug: Normal crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal crystalloid solution (control)
Trial: 7238015
Drug: 21-day patch
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day patch testing method
Trial: 6108123
Drug: Temazepam 40
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temazepam 40 mg
Trial: 30361675
Drug: Zein-ALA nanosphere
RxNorm normalized name: Zein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zein-ALA nanosphere formulation (F3)
Trial: 30361675
Drug: Marketed tablets
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed tablets
Trial: 18539007
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day of oral DHA
Trial: 18539007
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of oral DHA
Trial: 18539007
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day of oral DHA
Trial: 11854727
Drug: WASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WASA therapy (warfarin and aspirin)
Trial: 11854727
Drug: ASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA therapy (aspirin alone)
Trial: 11854727
Drug: WASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WASA therapy
Trial: 23558875
Drug: ASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA therapy
Trial: 11854727
Drug: Vein grafts
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein grafts with WASA therapy
Trial: 11854727
Drug: Vein grafts
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein grafts with ASA therapy
Trial: 2209656
Drug: Both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both agents (99mTc‐MIBI and 201Tl)
Trial: 31985049
Drug: STS101 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STS101 5.2 mg
Trial: 31985049
Drug: STS101 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STS101 1.3 mg, 2.6 mg, 5.2 mg
Trial: 30563778
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg
Trial: 30563778
Drug: Pridopidine 67.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 67.5 mg
Trial: 30563778
Drug: Pridopidine 112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 112.5 mg
Trial: 26492402
Drug: Dose-escalated intensity-modulated
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision
Trial: 26492402
Drug: IMPORT HIGH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPORT HIGH trial protocol for target volume and OARs dose constraints
Trial: 26492402
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of clip information for breast treatment verification
Trial: 26492402
Drug: CT guided
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT guided planning with full three-dimensional dose compensation
Trial: 21620725
Drug: Normal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal fluid intake (NFI: 2 L/day)
Trial: 21620725
Drug: High fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fluid intake (HFI: 4 L/day)
Trial: 19499846
Drug: metronidazole 750
RxNorm normalized name: metronidazole 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronidazole 750 mg/day
Trial: 15234855
Drug: Standard condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard condition (twice-yearly Project RESPECT individual counselling)
Trial: 12082261
Drug: ACE-inhibitor (Spirapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor (Spirapril - 6 mg/day)
Trial: 12082261
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (Isradipin - 5 mg/day)
Trial: 12082261
Drug: Beta-1-blocker (Talinolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-1-blocker (Talinolol - 100 mg/day)
Trial: 12082261
Drug: Diuretic (Indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (Indapamide - 1.5 mg/day)
Trial: 9926187
Drug: Oxycodone (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Paracetamol (1000 mg three times a day)
Trial: 9926187
Drug: Oxycodone (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Ketoprofen (100 mg three times a day)
Trial: 9926187
Drug: Oxycodone (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0.03 mg/kg via PCA)
Trial: 2200257
Drug: Metoprolol OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol OROS (14/190 mg)
Trial: 1974382
Drug: Slow-release (SR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release (SR) metoprolol (200 mg)
Trial: 1974382
Drug: Long-acting (LA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting (LA) propranolol (160 mg)
Trial: 7011110
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg R 41 468 (acute intravenous administration)
Trial: 7011110
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg R 41 468 t.i.d. (oral treatment for 8 days)
Trial: 7011110
Drug: R 41
RxNorm normalized name: Durahesive Wafer 41m 4x4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 41 468 (oral maintenance therapy for 3 weeks)
Trial: 30079636
Drug: Both biologics
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both biologics (Proposed biosimilar and Reference pegfilgrastim)
Trial: 21221501
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral erythromycin (6 mg/kg/day, in four doses over ten days)
Trial: 15542792
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 or 5 mg once per day for 12 months
Trial: 9730852
Drug: Subcutaneous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GLP-1
Trial: 2918846
Drug: Colestipol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol (15 g/d)
Trial: 2918846
Drug: Fenofibrate (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (0.25 g/d)
Trial: 26678626
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg daily in addition to standard medical therapy
Trial: 17157756
Drug: Oxygen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen (4 L/min via nasal prongs)
Trial: 17157756
Drug: Oxygen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen (4 L/min via nasal prongs) in hypoxic patients
Trial: 11409185
Drug: Troxerutin 150
RxNorm normalized name: troxerutin
DrugBank: Troxerutin (DB13124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin 150 mg and carbazochrome 1.5 mg, administered intramuscularly (one ampoule) twice daily for one week
Trial: 11409185
Drug: Carbazochrome alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbazochrome alone, administered intramuscularly (one ampoule) twice daily for one week
Trial: 8220919
Drug: Flurbiprofen LAT
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen LAT (40 mg, applied via a non‐woven polyester‐backed patch, 12‐hourly over 14 days)
Trial: 8220919
Drug: Control (non-medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-medicated patch)
Trial: 29661699
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg twice daily)
Trial: 3026294
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg twice daily)
Trial: 2832575
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg twice daily) + Hydrochlorothiazide (25 mg twice daily)
Trial: 31021713
Drug: Estrogen hormone
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen hormone therapy (HT)
Trial: 30701936
Drug: Classical triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical triple scheme of first-line ET (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day) for 10 days
Trial: 30701936
Drug: Classical triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical triple scheme of ET with rebamipide (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day, rebamipide 100 mg 3 times a day) for 10 days
Trial: 26244602
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol (PS) consumption (2 g/day for 4 weeks)
Trial: 19220533
Drug: One oral
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral glucose-lowering agent
Trial: 19220533
Drug: Two oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two oral glucose-lowering agents
Trial: 17014562
Drug: temocapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temocapril (1 mg)
Trial: 17014562
Drug: losartan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (12.5 mg)
Trial: 17014562
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy
Trial: 10959739
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg once weekly
Trial: 10959739
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg weekly for 4 weeks
Trial: 7690382
Drug: Midodrine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (2.5 mg intravenously)
Trial: 29437614
Drug: Vaborbactam alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaborbactam alone (250 to 2000 mg)
Trial: 29437614
Drug: Meropenem alone
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem alone (1000 to 2000 mg)
Trial: 29437614
Drug: Vaborbactam and
RxNorm normalized name: meropenem and vaborbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaborbactam and Meropenem in combination
Trial: 19707144
Drug: Conventional suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional suspension laryngoscope
Trial: 15707491
Drug: Prolonged conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged conservative treatment under supervision of the general practitioner
Trial: 12672914
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of soy nuts delivering 6.6 mg daidzein and 9.8 mg genistein
Trial: 12672914
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of soy nuts delivering 13.2 mg daidzein and 19.6 mg genistein
Trial: 12672914
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of soy nuts delivering 26.4 mg daidzein and 39.2 mg genistein
Trial: 8265876
Drug: Resistive loads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistive loads increased from 0 to 24 cm H2O/l/s in 1, 3 or 6 steps or decreased in 6 steps
Trial: 31950923
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg silodosin for 10 days
Trial: 28281972
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy WBRT + simvastatin 80 mg/day
Trial: 22470429
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/d
Trial: 16041191
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 U subcutaneously (s.q.) twice daily
Trial: 16041191
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 U subcutaneously (s.q.) three times daily
Trial: 12446055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PET and clinical parameters
Trial: 10336532
Drug: Ibuprofen (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2400 mg p.o.)
Trial: 8938155
Drug: HBIg immunoprophylaxis
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIg immunoprophylaxis (10,000 IU monthly)
Trial: 27506803
Drug: vBloc therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vBloc therapy
Trial: 22366365
Drug: Hyaluronate injection
RxNorm normalized name: hyaluronate Injection
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronate injection (once a week for 3 weeks)
Trial: 22366365
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (once)
Trial: 22366365
Drug: Hyaluronate injection
RxNorm normalized name: hyaluronate Injection
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronate injection
Trial: 11891668
Drug: Diltiazem slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem slow releasing formulation (90 mg)
Trial: 11891668
Drug: Diltiazem moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem moderate releasing formulation (90 mg)
Trial: 11891668
Drug: Diltiazem fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem fast releasing formulation (90 mg)
Trial: 11891668
Drug: Diltiazem oral
RxNorm normalized name: diltiazem Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem oral solution (90 mg)
Trial: 9865999
Drug: ML 250
RxNorm normalized name: MOXIFLOXACIN 1.6MG/ML 250ML BAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML 250 IUD
Trial: 8588962
Drug: Biodegradable implants
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable implants (self‐reinforced poly‐L‐lactide wire combined with self‐reinforced polyglycolide screw or self‐reinforced poly‐L‐lactide plug)
Trial: 8588962
Drug: Metallic implants
RxNorm normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metallic implants (tension band wiring, Kirschner wire and metallic cerclage wire)
Trial: 21775106
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 156 mg
Trial: 21775106
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 234 mg
Trial: 19467177
Drug: Omalizumab (minimum,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (minimum, 0.016 mg/kg per IgE IU/mL every 4 weeks)
Trial: 16924047
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light treatments (3 treatments at 1-month intervals)
Trial: 9121357
Drug: Tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1 or 2 mg twice daily
Trial: 30630795
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin calcium (subcutaneous injection for 5 days)
Trial: 30630795
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-coagulant agent)
Trial: 27272517
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (830 nm wavelength, power 150 mW, spot size 1 cm², 30 s per cm², energy density 4.5 J/cm²)